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Schizophrenia is a neurodevelopmental psychiatric disorder affecting approximately 0.5-1% of 
the world’s population. The symptoms of schizophrenia are positive, negative, and cognitive in 
nature, but the effects of schizophrenia have far more widespread effects than these. There are 
several causative theories of schizophrenia, including the dopamine hypothesis, glutamate 
hypothesis, dendritic spine abnormalities, and immune system involvement. These theories have 
provided proposed pharmacological targets, giving rise to numerous antipsychotic drugs. Despite 
the modest effectiveness of antipsychotic drugs, their systemic side effects are severe and 
plentiful. These side effects only add to the countless, inherent side effects that accompany this 
disease, the most notable of which are described in this review. Quality of life is severely 
impaired in schizophrenia patients, with stigma being a significantly contributing factor. This 
review, as well as the accompanying dance video, aim to portray the large extent to which 




Schizophrenia (SCZ) is a neurodevelopmental psychiatric disorder that impairs perception, 
cognition, and motivation in those afflicted.1 This disorder’s impairments reflect alterations in 
neuronal circuitry within and across multiple brain regions.2 SCZ affects approximately 0.5-1% 
of the world’s population, and beyond the individual impact has a large economic, societal, and 
familial burden. Schizophrenia is a highly heritable disease with a lifetime prevalence of 0.4%.3 
Its onset occurs in late adolescence or early adulthood, and over time bears progressive 
academic, functional, and social impairment.4 The highest age range of incidence among men is 
10-25 and among women 25-35.5 Schizophrenia is also more commonly diagnosed in males than 
females (a 1.4:1 ratio) and males have poorer responses to treatment and poorer outcomes.2 The 
lifespan of individuals with SCZ is reduced by over 20 years, and the primary causes of death are 






      
Symptoms 
There are three main types of symptoms in SCZ: positive, negative, and cognitive.7 Positive 
symptoms include bizarre trains of thought, hallucinations and delusions; negative symptoms 
include apathy, poor rapport, lack of spontaneity, motor retardation, disturbance of volition, 
blunted affect, emotional withdrawal, and passive behavior; cognitive symptoms include 
distractibility, poor attention, and working-memory deficits. Abnormal circadian rhythms have 
also been observed in patients with SCZ.4 
 
Risk Factors  
Risk factors for SCZ are both environmental and genetic.1 People born in an urban environment 
have two times the risk of developing SCZ than those born in a rural environment. Some studies 
suggest that even just living in a city, regardless of birthplace, raises risk for SCZ. Moreover, 
migrant populations, especially ethnic minorities, face a higher risk of incidence.8 It has also 
been suggested that those who chronically use marijuana during early adolescence face 
heightened risk as well.7 For further risk factors, see Figure 1.10 
 
 
Figure 1: Environmental risk factors that increase odds of developing SCZ.10 
 
Genetic risk factors for SCZ also play a role. Common allelic variants and rare copy number 
variants have been associated with SCZ.11 The genetic component of SCZ is well supported as 
the rate of SCZ is 6-17 times higher among first degree relatives2 and 40-50 times higher in a 
monozygotic twin of an affected individual compared to the general population.12 Rates of 
schizophrenia among relatives of schizophrenic patients are significantly heightened (Figure 2).10 




      
 
 
Figure 2: Percent of first, second, and third degree relatives of SCZ patients at risk for developing SCZ.10 
 
Neural Abnormalities  
The interaction of environmental exposure and genetic predisposition produces the effects of 
altered neurodevelopment that manifest in this behavioral syndrome.2 The altered connectivity 




There are a number of hypotheses regarding the causation of SCZ, including dopamine, 
glutamate, dendritic spine abnormalities, and immune system involvement. The dopamine and 
glutamate hypotheses are the primary causative theories, and though the exact abnormalities of 
these two neurotransmitters vary between the hypotheses, their effects are the same (Figure 3).13 
 
 





      
 
Dopamine Hypothesis  
The dopamine hypothesis of SCZ was the initial and remains the most common theory.14 
Dopamine is a neurotransmitter involved in regulating reward, locomotion, behavior, learning, 
and emotion. Excess dopamine transmission is thought to play a role in the pathophysiology of 
SCZ.15 Dopamine belongs to the catecholamine family of neurotransmitters and is produced in 
the substantia nigra and ventral tegmentum.16 While the original theory proposed hyperactive 
dopamine transmission, the “revised dopamine hypothesis” has offered a far more nuanced view 
of dopamine abnormalities in SCZ patients. The revised version of this theory proposes 
hyperactive dopamine transmission in the mesolimbic areas and hippocampus, hypoactive 
transmission in the prefrontal cortex, and general dopamine dysregulation in the amygdala and 
prefrontal cortex (Figure 4).  
 
 
Figure 4: Brain pathways in which dopamine plays a role in SCZ.16 
 
It is known that dopamine in the basal ganglia is involved in mediating motivation, learning, and 




      
However, it is more difficult to link negative and cognitive symptoms to dopamine 
abnormalities, a limitation of the theory that has become increasingly apparent in the last 20 
years and has given rise to another emergent theory: the glutamate hypothesis.18  
 
Glutamate Hypothesis 
The negative and cognitive symptoms of SCZ may be better linked to the glutamate hypothesis.18 
Glutamate is the most abundant neurotransmitter in the body, as well as the most excitatory. It is 
also the precursor for a γ-aminobutyric acid (GABA), the most inhibitory neurotransmitter. 
Glutamate acts on ionotropic N-methyl-D-aspartate receptors (NMDARs).  
 
In the glutamate hypothesis, dopaminergic deficits are acknowledged only as secondary to 
underlying glutamatergic dysfunction. The glutamatergic model has emerged based upon 
observations of psychomimetic agents like phencyclidine (PCP) and ketamine. Phencyclidine 
and ketamine induce similar symptoms to those observed in SCZ: positive, negative, and 
cognitive. PCP and ketamine are non-competitive NMDAR antagonists that block NMDA-based 
neurotransmission. NMDARs are ionotropic glutamatergic receptors located on brain circuits 
that regulate dopamine release via a GABAergic neuron. Consequently, the mechanism of action 
and effects of PCP and ketamine can be studied to better understand SCZ.  
 
 
Figure 5: A. NMDAR complex. B. NMDAR hypofunction on GABAergic neurons causing excitotoxicity.
19 
 
The main conjecture of the glutamate hypothesis is that patients with SCZ have a deficiency in 
NMDARs, the receptor acted upon by glutamate. This deficiency prevents NMDARs from being 




      
NMDARs is critical for learning and memory processes as well as cortical plasticity and 
maturation.19 NMDAR hypofunction on GABAergic neurons causes a disinhibition of pyramidal 
neurons that release glutamate, ultimately causing excitotoxicity (Figure 5).  
 
Further emphasizing the importance of NMDAR hypofunction in the cortex are the facts that less 
co-agonists (which are required along with glutamate to activate NMDARs) of NMDAR are 
observed in SCZ patients and several risk genes for SCZ are on NMDA receptor proteins.18 
NMDAR deficiency is acknowledged to be a key abnormality in SCZ. 
 
Dendritic Spine Abnormalities 
Beyond these two theories of causation, the pathophysiology of SCZ has also been attributed in 
part to deficits in dendritic spines (Figure 6).2 Dendritic spines are protrusions from dendritic 
shafts that are the targets of axon terminals. They are the location of most excitatory synaptic 
connections. Though decreased dendritic spine density in patients with SCZ has been observed in 
multiple neocortical areas, they are best characterized in SCZ in neocortex layer three pyramidal 
neurons. Deficits in dendritic spines arise during development and are likely a result of 
disturbances in molecular mechanisms that underlie spine formation, pruning, and/or 
maintenance. Experimental models have shown that spine deficits are associated with 
impairments in working memory, attention, sensory motor processing, and sociability, all of 
which are cognitive symptoms of SCZ. It is proposed that antipsychotic drugs (APDs) are not a 
contributing factor to this lowered spine density. 
 
 




      
 
In addition to lowered spine density in layer three pyramidal neurons, other dendritic spine 
abnormalities have been observed in non-cortical areas like the hippocampus and striatum. In the 
hippocampus, the smaller volume and altered activity seemed to affect performance on some 
memory tasks.21 However, studies on the morphological changes of dendritic spines in this area 
are mixed and preliminary.2 In the putamen patch of the striatum, there is a higher total synaptic 
density of GABAergic medium spiny neurons, where cortico-limbic inputs are received.22 This 
area projects to the substantia nigra pars compacta, where they inhibit dopaminergic neurons. It 
is hypothesized that this may be a compensatory mechanism to quiet overactive dopamine 
neurons.2 
 
Though dendritic spines can be difficult to study because they are dynamic structures changing 
with varying hormone levels, environmental enrichment, drug use, learning, and synaptic 
activity, it is generally accepted that alterations in dendritic spines play a role in the pathology of 
SCZ.  
 
There are a few molecular mechanisms that underlie altered dendritic spine density in SCZ. It is 
proposed that glutamate stimulation causes synaptic strengthening and an increase in spine 
density that is dependent upon disrupting septin barrier filament to allow potentiation.23 
Mutations to genes that prevent this (i.e. Cdc42 and Cdc42EP3) are risk factors for SCZ. Cdc42 
is a RHO GTPase that is important for intracellular signaling, actin remodeling, and increasing 
spine formation. In contrast, Cdc42EP3 inhibits these processes. In SCZ, Cdc42 levels are lower 
while Cdc42EP3 is elevated, an imbalance that prevents spine enlargement and causes neuronal 
loss.  
 
Another underlying molecular mechanism involves the C4 complement protein. C4 is an 
opsonizing protein in the classical complement pathway and is also involved in synaptic pruning 
as it is allowed to accumulate on neuronal spines. C4 is overexpressed and/or mutated in a SCZ 
brain, leading to excessive complement activation on neurons; this is an indicator for the brain 





      
Immune System 
In addition to the aforementioned causative theories of SCZ, genetic, biomarker, and imaging 
studies have shown the involvement of the immune system.25 Though the immunological 
component of SCZ is only partly elucidated, the observations in this area are well founded. The 
increased risk of SCZ patients and their relatives for autoimmune diseases and vice versa is 
indicative of a deregulated, compromised central nervous system (CNS) immune process. 
However, it is inconclusive in postmortem studies whether there is a net effect of immune 
activation of the CNS. 
 
The most notable immunological finding in the meta-analysis conducted by van Kesteren et al. is 
that of increased microglial density in SCZ.25 Microglia are myeloid cells that have entered the 
CNS during embryonic development. They migrate to the site of an injury, such as infection, 
acute trauma, or neurodegeneration, to proliferate. Psychological stressors early in life and 
adulthood can cause elevated microglial activity, especially in the hippocampal regions. In 
childhood increased microglial density is associated with an increased risk of developing 
psychotic disorders in young adulthood.26 
 
Other immunological abnormalities include an increased frequency of seroconversion (the time 
period when specific antibodies develop and become detectable in blood to certain pathogens) in 
patients with SCZ, as well as an upregulation of pro-inflammatory genes, including interleukin 
(IL) 1, IL-6, and TNF.25 This increase in pro-inflammatory gene expression as well as 
microglial density is more pronounced in the temporal cortex, where higher order emotional 
processing and sensory and cognitive integration take place.  
 
Though these causative theories vary in their approach and focus, they all play an integral part in 
piecing together the puzzle of this disease. They also help elucidate important targets for new 
treatments and therapies.  
 
Treatments 
Antipsychotic drugs were first introduced in the 1950s.25 Their major mechanism of action is as 




      
effect on the cognitive or negative symptoms of SCZ.2 Antipsychotic action occurs when more 
than 65% of striatal D2 receptors are occupied by the drug.27 Antipsychotic drugs cause many of 
the negative metabolic side effects that will be discussed in the next section.6 Though APDs have 
improved and second-generation drugs have fewer metabolic side effects than first-generation 
medications, many patients struggle with APD induced weight gain and its downstream effects 
on metabolism. Beyond their metabolic consequences, APDs have wide ranging effects on the 
whole body, including myocarditis, cataracts, movement disorders, elevated prolactin levels, 
sexual side effects,28 and decreased fertility.3 Non-adherence to treatment regimens is as high as 
50% in SCZ patients.29 There is clearly a need for new biological targets and therapeutics.2 
 
Beyond medication, lifestyle interventions could help ease the symptoms of SCZ.29 With help, 
many of the social factors that exacerbate schizophrenia could be ameliorated. Such factors 
include leisure-based physical inactivity, poor diet, lower education, poverty, smoking (which is 
as high as 75% in patients with SCZ) and substance abuse. Potential therapies for future 
exploration to work to this end include fitness training, microbiome treatment to change energy 
intake and metabolism to impact dopamine levels, chronobiologic interventions to adjust the 
day/night cycle of patients to match actual day/night cycles, and increasing energy expenditure 
through sport in order to increase dopaminergic signaling.4  
 
Pathophysiological Consequences of SCZ and Its Treatment 
Schizophrenia, though a neurodevelopmental disorder, impacts far more than an afflicted 
individual’s brain. This review aims to explore the various effects of SCZ on the whole body to 
better understand the disease and the burden it imposes on patients. Furthermore, it is a goal of 
this review that in compiling the extensive effects of SCZ on the whole body, and portraying 
those both scientifically and artistically, that both medical professionals and the general public 




There is a strong correlation between SCZ and obesity. A study by Allison et al. found that 42% 




      
Obesity in patients with SCZ can partially be accounted for by an unhealthy lifestyle and 
personal genetic profile. However, antipsychotic drugs, especially second-generation ones, 
contribute to the prevalence of obesity in 40-60% of people receiving medication.29 There is a 
typical weight gain of 3.8kg in drug-naïve patients after starting antipsychotic treatment in the 
first three months of treatment.30 
 
Proposed Mechanisms of Action  
The mechanism of antipsychotic induced weight gain is fairly well-understood. One mechanism 
of action relates to the antihistaminergic properties of many APDs.29 Olanzapine, which has the 
highest affinity for histamine receptors,29 and clozapine block histamine H1 and H2 receptors.4 
This weakens histamine-mediated satiety signals in the hypothalamus where histamine helps 
relay satiety and hunger signals. This is not the sole mechanism, however, because even drugs 
that don’t have antihistaminergic properties cause weight gain. As such, there is a consensus that 
antipsychotics, though diverse and numerous, share antagonistic action on the D2 receptor, 
which blocks phasic dopamine effects in the striatum and other parts of the brain. This disrupts 
glucose regulation and has two effects on behavior: first, decreased motivation to move, and 
second, increased motivation to ingest a high-caloric diet. 
 
Another potential explanation for the prevalence of obesity in mentally ill patients (not just SCZ) 
is altered reward anticipation, which is in turn related to striatal dopaminergic dysregulation.4 
Striatal dysfunction is supported as one of the core pathological features of SCZ and provides a 
link between weight gain and SCZ. Neuroimaging techniques show decreased striatal activation 
in drug-naïve and un-medicated patients. These are the same participants at high risk for 
psychosis. Reward anticipation is the dopamine response induced after the input of a conditioned 
stimulus that signals incentive. For example, a rodent that received a food pellet after pushing a 
button; prior to learning the striatum and dopamine neurons respond to getting the reward (or 
food pellet in this scenario), whereas after learning the striatum responds to the conditioned 
stimulus (or pushing the button). Because there is a reduction in striatal D2 receptors found in 
pathologically obese participants, similar to patients with SCZ and other addiction disorders, it is 
suggested that reward anticipation is decreased. Individuals compensate for this by eating 




      
 
The degree of reduced reward anticipation is linked to symptom severity and altered dopamine 
activity because treatment with antipsychotics partially normalizes this dysfunction. It should 
also be noted that chronic changes in eating (a high-fat, high-sugar diet) can cause down-
regulation of D2 receptors in animals.  
 
Another mechanism of weight gain in SCZ is explained by in the neuro-endocrine model.29 This 
suggests that dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis causing higher than 
normal serum cortisol results in less circulating levels of leptin. A decrease in leptin, responsible 
for signaling satiety, leads to increased appetite, weight gain, excessive accumulation of visceral 
fat, insulin resistance, and dyslipidemia. A genetic rationale for weight gain in SCZ is supported 
by the statistic that 50% of patients with SCZ have a familial history of type II diabetes (T2D) 
versus 4.6% of non-affected individuals. One explanation for this is that fetal alpha-melatonin 
stimulating hormone (thought to be a determinant of early fetal growth) is abnormally high in 
infants of people with diabetes. As such, this is thought to be an independent risk factor for SCZ 
via its effects on brain development and maturation. An alternative explanation is that a 
gestational zinc deficiency causes damage to organism that have a high zinc requirement, like the 
pancreas, which plays a large role in digestion and gastrointestinal health.  
 
Antipsychotic Drug Associated Weight Gain 
Olanzapine is the first line treatment for first episode SCZ.6 However, in a meta-analysis done by 
Allison and Casey, patients being treated with olanzapine had a mean weight gain 4.15kg over 
the course of 10 weeks, second only to the 4.45kg weight gain observed with clozapine.28 Of the 
second-generation APDs, olanzapine and clozapine are the two most commonly associated with 
diabetes. In a study by Koro et al. using the United Kingdom General Practice Research 
Database, of the 18,903 individuals with a diagnosis of SCZ those who received olanzapine had 
significantly increased odds of developing hyperlipidemia compared to those who didn’t receive 
any APDs and those who received a first-generation APD.31 Another study showed that time of 
treatment with olanzapine advanced time of diabetes onset.6 If giving during the first year of 
antipsychotic treatment, olanzapine was associated with a significantly shorter time to diabetes 




      
increased risk of diabetes. This altered trajectory can be explained by initial weight gain that 
adversely affects insulin resistance, or direct effects on pancreatic beta cells that cause a 
quickened diabetes onset in vulnerable individuals.  
 
Despite the well supported link between drugs like olanzapine, clozapine, and low potency first-
generation antipsychotics and diabetes, three months after the onset of diabetes the 
overwhelming majority of patients were still on those same high-risk drugs; only 6% switched to 
low-risk drugs.6 Of the patients diagnosed with diabetes, only 26.1 had been treated with one of 
the two low-risk drugs (aripiprazole and ziprasidone) prior to treatment with the high-risk drugs. 
These studies bring into question practitioners’ use of olanzapine as their first line treatment.  
 
Co-occurring diseases that contribute to obesity in SCZ include hypertension, coronary artery 
disease, osteoarthritis, type II diabetes mellitus, and stroke.28 Type II diabetes (T2D) in patients 
with SCZ is 2-4 times greater than the general population.29 It has a prevalence in SCZ patients 
between 10.8% and 14.9%, with an increased prevalence in older individuals, females, African 
Americans, and other non-whites. There are 41% of people under age 44 with a dual diagnosis of 
SCZ and diabetes, compared to just 30% of people under age 44 with just diabetes. 19% of 
people with dual diagnoses SCZ and diabetes died prematurely versus 9% with just diabetes. 
There’s even an increased risk for diabetes in first-degree relatives of those with SCZ. Beyond 
diabetes, 1 in 2 patients with SCZ are overweight, 1 in 5 have significant hyperglycemia, and at 
least 2 in 5 have lipid abnormalities.30  
 
Metabolic Syndrome 
Another co-occurring condition that co-exists with the other weight-related diseases discussed 
above is metabolic syndrome (MetS).29 Metabolic Syndrome is a cluster of risk factors including 
hyperglycemia, dyslipidemia, hypertension, a prothrombic state, and central obesity,29 the 
presence of three or more of which are symptomatic of having the disorder.30 Almost 1 in 3 
patients with SCZ suffer from MetS. The rate of incidence is 50% (two- to three-fold higher than 
the general population) in people with severe mental illness.29 The explanation for the prevalence 
of MetS in people with severe mental illness, including SCZ, is likely multi-factorial and 




      
cardiovascular disease, which will be expounded upon later in this review.30 The effects of SCZ 
do not stop with the cardiovascular system though, its consequences are far more widespread.  
 
Other Full-Body Effects 
Fertility 
Further investigation of the full body effects of SCZ lead to another important finding discussed 
extensively in a review and meta-analysis by Bundy et al., that of reduced fertility in patients 
with SCZ.3 Studies have found that in SCZ patients males have significantly fewer offspring than 
females. These abnormal fertility rates extend beyond the patients themselves, affecting relatives 
of SCZ patients as well. Siblings of patients have lower offspring compared with the general 
population, with the decrease in brothers being more prominent than in sisters. Results are 
somewhat inconsistent when it comes to studying the fertility of parents of patients with SCZ. A 
few reasons for the decreased fertility in SCZ patients include availability of sexual partners, 
emotional and social functioning, sexual desire and reproductive health, psychotropic 
medications, and drug, alcohol, and tobacco misuse. The disproportionate effect on men’s 
fertility is thought to be attributed to their earlier age of onset and poorer outcomes as well as 
poorer premorbid function prior to SCZ onset, thus limiting opportunities for potential 
parenthood. Taken in conjunction with the genetic component of SCZ already discussed, we 
arrive at a dilemma that has been coined the “Schizophrenia Paradox,” which raises the question 
of how genetic variants predisposing individuals to SCZ are maintained in the population despite 
imposing reduced biological fitness. There are a few proposed mechanisms that could aid in 
explaining this paradox. First is the generally accepted idea that SCZ is under polygenic control. 
Following this line of thinking, there is potentially a set of loci that together influence disposition 
to paranoid thinking, which, if fall at one extreme of the phenotypic spectrum, will put an 
individual at greater risk of developing the disease.  The association between SCZ and older 
paternal age suggest that some cases of SCZ may be due to de novo mutations in the male germ 
line. Rare copy number variations (CNVs) have also emerged as a risk factor in some cases of 
SCZ. These de novo mutations arising from both the male germ line as well as inherited from 






      
Hypothalamus 
Abnormalities in gonadal and adrenal hormone levels point to hypothalamic structure 
abnormalities in SCZ patients, more specifically an enlarged hypothalamic volume (Figure 7).32 
This enlargement is most notable in mammillary bodies and the paraventricular nucleus (PVN). 
Rates of dysfunction range between 50% and 70% and manifest in endocrine and stress-response 
dysfunction, such as anxiety. This enlargement is more prevalent in women than men, more 
severe in multiplex than simplex cases, and more pronounced on the right side. The 
hypothalamus is also significantly larger in nonpsychotic first-degree relatives of SCZ patients, 
an observation that is also stronger in multiplex cases. The enlarged hypothalamus in SCZ 




Figure 7: Hypothalamic enlargement in SCZ.
32 
 
Potential explanatory models for this phenomenon include increased number of hypothalamic 
neurons, neuron size, or increased neuropil resulting from disruption in normal brain 
development. This could be attributed to disrupted aromatization of testosterone to estrogen, 
affecting both males and females via a similar mechanism. Developmental apoptosis is regulated 
in part by testosterone and estrogen, so the disruption of aromatization mid-gestation will result 
in less hypothalamic apoptosis and an increased number of neurons. This same effect is observed 




      
observed, resulting in the high androgen and low estrogen levels that alter normal developmental 
apoptosis.  
 
Paraventricular Nucleus  
Continuing in this extensive review article, Goldstein et al. discuss the enlargement of the PVN 
that also has many implications on the endocrine systems of patients affected with SCZ. In the 
PVN there is a high density of cortisol releasing hormone (CRH) neurons that also release 
norepinephrine (NE) as part of the stress response. Cortisol releasing hormone neurons are co-
localized with estrogen receptors (ERs), thereby suggesting the ERs play a role in PVN release 
of CRH. In major depression, an increase in hypothalamic volume as well as CRH neurons co-
localized with ERs was also observed, which may have implications in understanding SCZ. 
Moreover, abnormalities in the number of vasopressin and oxytocin neurons and hormone levels 
have been observed in SCZ regardless of APDs.  
 
Thyroid  
Another endocrine abnormality found in patients with SCZ is related to thyroid hormones. 
Psychotic symptoms, many of which resemble those in SCZ, may occur in patients with both 
sever hypo- and hyperthyroidism.33 In a study, serum thyroxine (T4), triiodothyronine (T3), 
reverse triiodothyronine (rT3), and thyroid stimulating hormone (TSH) levels were measured 
before and after 4 weeks of treatment with perazine, a phenothiazine derivative. The sample 
included 31 acutely ill patients, 19 SCZ patients in remission receiving no medication, 20 SCZ 
patients in remission taking medication, and 24 patients with residual-type SCZ. The only 
notable abnormalities in these hormone levels were observed in acutely ill patients. At the 
study’s start, levels of T4 were elevated, but levels of the other three hormones were normal. T4 
is correlated with severity of illness and degree of response to neuroleptic treatment. There was a 
significant fall in both T4 and rT3 in the fourth week, a decrease that was correlated with clinical 
response. This suggests that neuroleptic medications may affect thyroid hormone metabolism in 







      
Other Co-Occurring Conditions  
There is a strong, bidirectional relationship between SCZ and epilepsy.5 The risk of seizure 
disorders is five times higher among children with psychiatric diseases. A study by Chang et al. 
showed that epilepsy was almost six times higher among both children and adults with SCZ. One 
can turn to the shared susceptibility for these two diseases to explain this co-occurrence. Both 
share the same candidate genes, including the leucine-rich glioma inactivated 1 (LGI1) gene, 
which is involved in neurodevelopment and associated with febrile seizures and SCZ, as well as 
the CNTNAP2 gene, which is important in organizing myelinated axons but may disrupt 
neuroblast migration. Other environmental and neurobiological factors (i.e. cortical dysgenesis 
or diffusive brain damage) may also be contributive.  
 
Cardiovascular Disease as the Leading Cause of Death in Schizophrenia  
There is a three-fold increase in mortality rates in SCZ compared to the general population.34 
While the elevated risk of suicide and accidental death were previously reported to be the 
primary causes of premature death in SCZ, more recent work suggests premature mortality is due 
to cardiovascular disease. This is attributed to the higher prevalence of factors that heighten 
CHD risk, including smoking, unhealthy diet, physical inactivity, obesity, diabetes mellitus, 
hypertension, low high-density lipoprotein (HDL) cholesterol, lower quality primary chair, and 
APD induced weight gain. Diabetes mellitus is a particularly strong risk factor for cardiovascular 
mortality at a risk level approximately equal to that of a myocardial infarction.6 An increased or 
decreased risk of CHD is associated with particular APDs; olanzapine is associated with a 0.5% 
increase, quetiapine 0.3%, perphenazine a decrease of -0.5%, risperidone -0.6%, and ziprasidone 
-0.6%.27 These differences are attributed primarily to changes in HDL cholesterol levels.  
 
Cardiovascular disease has far reaching effects beyond their direct consequences on the 
cardiovascular system. Cardiovascular risk factors are also important risk factors in the 
development of dementia and other cognitive decrements, further speaking to the far-reaching, 
full body effects of SCZ.35 There is already an established relationship between high BMI and 
hypertension resulting in poorer cognitive performance even without SCZ36, but when diagnosed 
with both BMI/hypertension and SCZ cognitive performance worsens still.35 In studies 




      
measures of cognitive performance. A combination of SCZ and high BMI was modestly 
associated with worse verbal memory performance, though not at statistically significant levels. 
A combination of SCZ and hypertension, however, caused significant negative effects on 
immediate, delayed, and recognition memory, an overall poorer verbal memory performance; 
hypertensive SCZ patients performed significantly worse than their non-hypertensive 
counterparts.  
 
The proposed mechanism of action is related in part to atherosclerosis, as supported by the 
correlation between dementia and atherosclerosis severity. Other proposed mechanisms are 
nonvascular in nature. For obesity, it has been suggested that the direct action of adipocytes on 
neuronal tissue by releasing neurochemical mediators is a contributing factor.37 Leptin is another 
proposed mechanism. Leptin facilitates learning, spatial memory, and long-term potentiation.38 It 
is also shown to enhance NMDAR function and modulate hippocampal synaptic plasticity.39 
Higher levels of leptin are associated with high BMI.40 Leptin resistance, therefore, may provide 
the link between obesity and poor cognition.  
 
For hypertension it is thought that increased activation of the renin angiotensin aldosterone 
system (RAAS) may be a factor linking this condition to cognitive impairments.41 RAAS is 
activated when blood pressure is low and works to increase blood pressure by releasing 
hormones that promote water retention. Observations of mice show that increased RAAS 
activation impairs cognitive function and is ameliorated by angiotensin II type 2 receptor 
antagonists. Oxidative stress is another underlying mechanism that has been proposed.  
 
Quality of Life Issues 
Even in SCZ patients who are relatively healthy, concerns regarding quality of life (QOL) have 
been of increasing concern in recent years.42 Various studies have aimed to study quality of life 
in patients with SCZ. Such studies have found that the presence of positive and negative 
symptoms is correlated with poor QOL. Higher medication adherence, despite the negative side 
effects of many APDs, is associated with better QOL. The de-institutionalization movement of 
psychiatric patients that started in the 1960s has had significant impacts on QOL. At its start, this 




      
many patients victims of assaults or suicides. If patients did have family to help them, home care 
was often too difficult and intensive for families to maintain. Though these are still relevant and 
prevalent problems, new APDs and halfway houses have helped offer a better avenue for 
psychiatric patients to improve their QOL. 
 
Stigma 
Accompanying these quality of life concerns are the pervasive negative societal attitudes towards 
SCZ patients constituting stigma.43 Stigma is described as “a deeply discrediting attribute that 
reduces the bearer from a whole and usual person to a tainted, discounted one.”43 The bearer is 
usually seen as not having legitimacy to participate in social interactions, in part because he/she 
is perceived as dangerous and unpredictable. Though stigma varies across cultures, it is generally 
observed that SCZ patients experience a high level of stigma, which restricts many aspects of 
life. Common impacts of stigma include social exclusion, unsatisfactory housing, and restricted 
opportunities for employment and education. All of these severely decrease QOL. Stigma does 
not always come from external sources; self-stigmatization has a significant impact (both 
positive and negative) on self-esteem and self-efficacy.44 There is an inverse relationship 
between having a paid job and experiencing stigma. This may be due to the greater degree of 
self-esteem resulting from SCZ patients being ensured a job. Second, patients who achieve a 
higher level of functioning experience lower self-stigma, anticipated stigma, and participatory 
restriction. Third, knowledge (or lack of) about diagnosis and treatment for patients with SCZ 
influences the alienation component of stigma. As such, simple psychoeducation may help lessen 
stigma and improve QOL.  
 
Schizophrenia Expressed Through Art  
The arts have always been a means of communication, and in recent years have become an 
increasingly favored medium for the communication of scientific information.45 This is effective 
in that it targets the affective rather than the cognitive domain of learners, encouraging creativity 
by intuitive thinking and promoting more meaningful social change through public behavior, 





      
With its power to convey difficult social issues, the accompanying dance video aims to 
encourage such creativity, eagerness, and compassion with regard to SCZ. This video began as a 
collaborative project between colleagues who contributed to its creation through their 
videography and creative input. The aforementioned aspects of SCZ, particularly symptomology 
and quality of life struggles, are those that are conveyed artistically through the accompanying 
dance video and music. The movement and music portray the story of a young woman at the 
onset of her SCZ and the subsequent havoc it wreaks on not only her psyche but her whole 
person.  
 
It is clear that there is a need for better treatments for those plagued with SCZ. This need for 
treatment improvements extends far beyond actual medical treatments that must be enhanced to 
minimize adverse side effects and into the way that SCZ patients are treated in social and 
political contexts. It is the aim of this review that by spreading knowledge of the physiological 
basis of SCZ and expressing its full body effects through art that better understanding, humility, 
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